ISTH 2019

Australian and US researchers have genetically engineered a novel antithrombotic drug, which binds only to activated platelets at the site of a thrombus. By only binding to activated platelets, not sealing platelets, there is no risk of bleeding complications with the...

Australian and US researchers have genetically engineered a novel antithrombotic drug, which binds only to activated platelets at the site...

The rebalancing agent concizumab has the potential to fulfil a need for new treatment options across all haemophilia subtypes but importantly for patients with haemophilia B and inhibitors. Speaking at the ISTH Congress, Associate Professor Jan Astermark said that the US...

The rebalancing agent concizumab has the potential to fulfil a need for new treatment options across all haemophilia subtypes but...

Machine learning is either the future of medicine or a distraction from clinical medicine - if the lively discussion at ISTH Congress is anything to go by. The discussion was generated after Dr John Willan, from Oxford University Hospitals, told the...

Machine learning is either the future of medicine or a distraction from clinical medicine - if the lively discussion at...